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Abstract The interrelation between needs for care and
quality of life has been described and replicated by several
studies. The present work aims to add to the understanding
of longitudinal interrelations between needs for care,
quality of life, and other outcome measures by analyzing a
sample of patients at the onset of schizophrenia. This study
relied on data from the EUFEST trial, designed to compare
first- and second-generation antipsychotics during 1 year.
At baseline, 498 patients have been included. The first
(baseline) and the last assessment (12 months after base-
line) were used for the analyses. Predictors of quality of
life were determined using regression analyses. We tested
the complex longitudinal interrelations between baseline
and outcome measures with structural equation models.
Unmet needs were not definitively confirmed as a predictor
of subsequent quality of life, unless unmet needs changing
to no needs were separated from unmet needs changing to
met needs. Each unmet need that changed to no need
enhanced the quality of life (mean score 1–7) by 0.136
scale points. This study suggests that when studying quality
of life and needs for treatment, it is crucial to differentiate
whether unmet needs disappeared or whether they were
met, as the former has a stronger impact on quality of life.
Keywords Psychosis  First episode  Quality of life 
Treatment needs  Longitudinal analysis
Introduction
Addressing the needs of psychiatric patients has become an
important indicator for assessing the quality of mental
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health services. It is understood that each patient has
individual needs, but that there are illness-specific needs
common to patient groups. Needs of patients could, in
principle, be satisfied by providing effective treatment.
Needs are commonly differentiated into met and unmet.
Unmet needs are ongoing serious problems of an individual
patient, whether or not help is provided, whereas met needs
are absent or moderate problems because help is provided
and successful [23]. For example, an unmet need is when
someone does not know where to live after leaving the
hospital. The need is met when this person has an interim
solution and receives help with finding a new apartment.
Met needs are further distinguished from no needs, as they
continue to be needs despite the temporary relief afforded
by treatment. For example, no need is when the living
situation of a patient is satisfactory. If previously unmet
needs can be satisfied, or if the number of unmet needs has
simply declined over time, it is assumed that treatment has
been effective [31]. Although the assessment of treatment
needs is widely used, its validity as an outcome measure
remains contested as oversimplifying the process of clini-
cal decision making and individual recovery processes of
patients [24].
It is assumed that a change from unmet to met needs of
patients should improve their quality of life [31].
Enhancing quality of life is a major goal of treatment,
especially in patients suffering from severe and chronic
mental disorders. Quality of life encompasses, as a broad
outcome measure, satisfaction with several domains of
individual life. The domains of quality of life and the
domains of needs overlap in part (e.g., living situation,
work, and social relations) [26]. At least a weak interre-
lation of the two concepts can be anticipated.
Usually, needs are assessed with structured interviews,
the most common being the Camberwell Assessment of
Need (CAN) [23] and the Needs for Care Assessment
(NCA) [5]. Cross-sectional studies [3, 9, 10, 32, 35, 39]
have confirmed the interrelation between unmet needs and
quality of life including patients with high, medium, and
low levels of functioning [3]. For met needs, the interre-
lation with quality of life was less consistent. Some studies
found a negative association (the more met needs the lower
the quality of life) [32, 39], others did not find such an
association [10]. The assumption that more met needs
would be associated with higher quality of life was not
confirmed.
However, cross-sectional studies are not sufficient to
resolve questions of causal interrelations. Longitudinal
association is one criteria of establishing causality [4]. The
few longitudinal studies testing the interrelation of quality
of life and needs yielded inconsistent results. Slade et al.
found that the average level of unmet needs and changes in
unmet needs preceded quality of life [30]. Patient-rated
unmet needs were a stronger predictor of subsequent
quality of life than social role functioning, psychopathol-
ogy, satisfaction with services, and therapists’ ratings of
needs [31]. Hansson and Bjo¨rkman [9], on the contrary, did
not find any longitudinal associations between needs and
quality of life.
The aim of the present study was to gain greater
insight into the longitudinal interrelation between quality
of life, unmet needs, symptom severity, clinical status,
and social functioning. As a met need is defined as a need
that is met by treatment, it has to be differentiated from a
need that has disappeared during treatment. Therefore, we
were interested whether the change from unmet needs to
met needs [31], but also to no needs is associated with
improvement in quality of life. The secondary aim was to
describe the interrelation of needs and quality of life in a
homogenous sample of patients moving from the acute
first episode to the remission and stabilization phases of
schizophrenia.
Methods
Database
The present study used the data of the European First-
Episode Schizophrenia Trial (EUFEST) [8, 15]. The
EUFEST study aimed to compare second-generation an-
tipsychotics with low doses of haloperidol [15]. The main
outcome measure was 1-year retention rates of medica-
tion. In addition, a battery of outcome and diagnostic
measures was assessed at several defined points in time.
The present study includes psychosocial and psycho-
pathological outcome measures assessed at baseline and
after 12 months, as needs and quality of life were asses-
sed simultaneously only twice, at the beginning and end
of the study. Although the EUFEST trial addressed some
weaknesses of previous antipsychotic drug trials (for cri-
tique of previous studies see [19]), other methodological
aspects can be criticized: Among other, EUFEST was not
blinded [8] and thus is supposed to favor all second-
generation antipsychotics [19]; also, the analytic strategy
used in EUFEST has been criticized [7], but most cri-
tiques are focused on the comparison of first- and second-
generation antipsychotics. The present study does not
analyze medication, and therefore most of these limita-
tions do not apply. Limitations relevant to this study are
discussed in the limitations section.
Sample
Fifty centers from 13 European countries and Israel were
selected for participation. Altogether, 1,047 patients were
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screened for eligibility between the December 2002 and
January 2006. Inclusion criteria were age between 18 and
40 years, and a DSM-IV diagnosis of schizophrenia,
schizophreniform disorder, or schizoaffective disorder,
onset of positive symptoms dating back at most 2 years;
use of antipsychotic drugs for at most 2 weeks in the
previous year or for at most 6 weeks at any time; and no
known intolerance or contraindication for one of the study
drugs. Diagnoses were confirmed by the International
Neuropsychiatric Interview (MINI plus [29]). 498 patients
gave informed consent and were randomly allocated to five
treatment groups. The study protocol was subjected to the
local ethic committees or review boards according to the
country specific laws.
Attrition rate
Of the 498 patients initially included, 342 (68.7%) com-
pleted according to the protocol. Of the 156 (31.3%)
withdrawals, investigators withdrew 6 and 4 did not meet
the inclusion criteria. The remaining 146 patients have
decided by themselves to quit the study.
Measures
Met and unmet needs were assessed using the CAN [23].
The CAN is a 22-item measure encompassing several
domains of life that are potentially problematic for people
suffering from mental illness. Domains of life are for
example: ‘‘psychotic symptoms,’’ ‘‘accommodation,’’ ‘‘day
time activities,’’ ‘‘intimate relationship, but also ‘‘trans-
port’’ or ‘‘money.’’ For each domain, the presence of needs
and the coverage of needs by treatment are collected.
Validity and reliability of the CAN are considered to be
acceptable [23]. The construction of adequate summary
indices is controversial [21, 36–38], but most studies rely
on sum scores of met and unmet needs. The CAN allows
for ratings by patients and ratings by professionals (e.g.,
therapists, caseworkers, or research assistants). The Kappa
coefficients for the agreement between ratings of profes-
sionals and patients are between 0.18 and 0.53 [11, 12, 18,
33, 34, 38]. In the present study, sum scores of patient-
rated met and unmet needs are used.
The Manchester Short Assessment of Quality of Life
(MANSA) [25] is a widely used measure of quality of life
encompassing 16 items, four questions about objective, and
twelve questions assessing subjective quality of life by
asking patients about their satisfaction with several
domains of life. Answers for subjective quality of life are
on a 7-point scale ranging from 1 = ‘‘could not be worse’’
to 7 = ‘‘could not be better.’’ We used the mean of the 12
patient-rated subjective questions to calculate a quality of
life score.
Other measures used in the present study were the
PANSS (Positive And Negative Syndrome Scale [16]), the
CDSS (Calgary Depression Scale for Schizophrenia [1])
measuring the level of depression in schizophrenia, and the
GAF (Global Assessment of Functioning [14]). The Hay-
ward Scale [17] was used to assess compliance (one-item
7-points rating scale with higher scores suggesting better
adherence), and prognosis was assessed using a 6-point
scale ranging from 1 = best to 6 = bad.
The PANSS measures positive and negative symptoms
of schizophrenia and general psychopathology. It is a
30-item structured interview scored by a trained rater and
lasts 30–40 min. Scores for positive and negative symp-
tomatology, general psychopathology, and a total score are
calculated.
The CDSS is a nine-item self-rating scale that assesses
depression in schizophrenia with good reliability [2]. From
all items, a total score (mean of ratings) is calculated. A
cutoff of seven points refers to a specificity of 82% and a
sensitivity of 85% for detecting major depressive episodes
[1].
Sociodemographic variables were assessed at baseline.
All other measures were assessed at least at visit 1 (base-
line) and visit 9 (after 12 months). Observer-rated mea-
sures were assessed by site coordinators or co-
investigators, e.g., psychiatrists (including trainees in psy-
chiatry), research nurses, or psychologists.
Statistical analyses
To determine whether values at baseline differed from
values at the 12-month follow-up, T tests for paired sam-
ples and Wilcoxon tests were used. All tests were calcu-
lated with PASW Statistics 18.0 for Windows.
Regression analysis
The dependent variable in regression analysis was the
mean of the 12 items of the MANSA measuring subjective
quality of life 12 months after the study begin. Independent
variables were the basic sociodemographic characteristics
(gender, age, years of education, occupied at baseline),
diagnosis, initial medication group (randomization), psy-
chosocial intervention (yes–no), and antipsychotic medi-
cation before the beginning of the study (yes–no); baseline
quality of life (MANSA sum score), number of met and
unmet needs, psychopathology (scores of the PANSS
positive and negative symptoms, and the CDSS total mean
score), and the global assessment of functioning (GAF)
score. Additionally, compliance (Hayward scale) and
prognosis were included. Only bivariate significant vari-
ables and positive and negative symptoms (because of their
importance), were selected for the models including several
Eur Arch Psychiatry Clin Neurosci (2012) 262:207–216 209
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predictors simultaneously. Regression models were esti-
mated using PASW Statistics 18.0 for Windows.
Structural equation models
Structural equation modeling (SEM) is the method of
choice to study (longitudinal) interactions when predictor
variables are closely interrelated (multicollinearity). To the
best of our knowledge, there are no studies using SEM to
inquire on the longitudinal association between needs and
quality of life, with the exception of two studies using
graphical chain modeling [27, 31].
We fitted two different structural equation models that
both allow for a temporal sequence of unmet needs and
change variables. The first aimed at replicating the results
of the regression analysis to provide a base for subsequent
models. The second model additionally included the
number of changes from unmet needs to no needs and from
unmet needs to met needs. Both models were developed
using a stepwise deletion of paths. Primarily, a saturated
model was fitted, with regression paths from all baseline
variables to both change variables (met to unmet needs and
met to no needs) and with regression paths from all vari-
ables to quality of life at follow-up. The model further
estimated correlations among baseline variables and cor-
relations among change variables. Starting from the satu-
rated model, the paths with the lowest significance were
omitted step by step, i.e., the model was run again after
each deletion. The models were fitted using Mplus [22].
The model fit was assessed as suggested by Yu [40].
Results
From baseline to follow-up at 12 months, 78.7% (263 of
334 completers with valid PANSS scores at both points in
time) reached a 50% reduction in the PANSS total score,
fulfilling the criterion for treatment success defined by
Leucht et al. [20]. Major depressive episode (MDE) mea-
sured with the CDSS was diagnosed in 36.1% (123 of 341)
at baseline; this was reduced to 3.5% (12 of 340) at
12 months. Most of the patients (completers) were in
inpatient treatment setting at the beginning of the study
(89.8%, 307 of 342) but only 4.7% (16 of 340) at follow-
up. In sum, clinical improvement in the total sample was
considerable.
Table 1 shows the descriptive statistics of quality of life
and needs, clinical and social functioning. At baseline,
study completers were more often female and had more
(met and unmet) needs, fewer psychosocial interventions,
lower quality of life, and better compliance as well as
prognosis. Fewer completers came from West Europe.
Figure 1 expresses follow-up values as proportions of
baseline values. Comparing change in different outcome
measures, it becomes clear that changes were most pro-
nounced in unmet needs rated by patients, positive symp-
toms (PANSS), and functioning (GAF score).
Predictors of quality of life using regression analysis
The baseline variables associated with quality of life at
follow-up were as follows: unmet needs, functioning
(GAF), depression (CDSS), prognosis of patient, psycho-
social intervention, gender, age, current occupation, and
years of education. Associations with outcome quality of
life changed in some time-dependent variables once base-
line quality of life was included. Table 2 shows the mul-
tiple regression analysis results for all bivariate significant
predictors of quality of life at follow-up. In multivariate
analyses, the model fit improved when baseline quality of
life was included as a predictor of quality of life assessed at
follow-up (Model 1 vs. Model 2 in Table 2). After
including baseline quality of life as a predictor, the baseline
assessments of depression, gender, and age remained sig-
nificant predictors of quality of life at follow-up (Table 2,
Models 2, 3). In contrast, the impact of unmet needs on
quality of life was no longer significant. Interestingly, more
depression at baseline was associated with higher quality of
life at follow-up. Younger female patients had higher
quality of life at follow-up.
Structural equation models
The first simple structural equation model led to nearly the
same results as the regression model 2 in Table 2 (Fig. 2).
The longitudinal association between baseline unmet needs
and follow-up quality of life approached P = 0.05. The
second model (Fig. 3) additionally included the number of
changes of unmet needs to no needs or to met needs, and
age and gender that were significant in regression model 3
(Table 2). Change from unmet needs to no needs was more
strongly associated with quality of life than change from
unmet needs to met needs (not significant). Fewer unmet
needs, more depression, higher baseline quality of life,
younger age, and being female were associated with higher
quality of life at follow-up. Higher depression scores at
baseline implicated more change to no needs, and there-
fore, higher quality of life at follow-up. Similarly, a higher
level of positive symptoms was associated with more
change from unmet needs to no needs. Younger female
patients also had more unmet needs changing to no needs.
Only depression and unmet needs were associated with the
change to met needs (higher depression scores were asso-
ciated with fewer changes to met needs).
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Discussion
The present study aimed to explore the temporal inter-
relation between quality of life, unmet needs, and
potentially associated clinical measures. It used a longi-
tudinal sample of patients suffering from first episodes of
schizophrenia. We believe there is no published study of
a comparably homogenous sample at the onset of illness.
Not surprisingly, there were marked improvements in all
social and psychopathological outcome indicators over
time. While previous studies [30, 31] found a
longitudinal interrelation between needs and quality of
life, this finding was not clearly confirmed by our study.
We used statistical techniques that allowed for a differ-
entiation between needs and the change from unmet
needs to no needs. In this sample of first-episode
patients, the change of unmet needs to no needs had a
stronger impact on quality of life than needs being met.
This is self-evident but indicates that the longitudinal
association between the two constructs depends not on
the mere reduction in, but on the specification what
happened to the unmet needs.
Table 1 Quality of life, needs, baseline sociodemographic data, clinical status, and social functioning
Baseline total Baseline completers Drop outs Difference drop
outs - completersa
Mean ± SD/
percent
N Mean ± SD/
percent
N Mean ± SD/
percent
N P
Age at baseline 25.98 ± 5.55 (498) 26.05 ± 5.64 (342) 25.83 ± 5.38 (156) 0.618
Gender (women) 40.2% (200) 43.6% (149) 32.7% (51) 0.024
Cultural region – – – 0.000
West Europe 34.9% (174) 28.9% (99) 48.1% (75) –
East/Central Europe 51.4% (256) 59.6% (204) 33.3% (52) –
Israel 13.7% (68) 11.4% (39) 18.6% (29) –
Occupation at baseline (yes) 46.6% (231) 46.5% (159) 46.8% (72) 1.000
Antipsychotic naı¨ve at baseline 32.5% (162) 30.7% (105) 36.5% (57) 0.216
Years of education 12.46 (493) 12.58 (341) 12.17 (152) 0.140/0.181
Medication
Haloperidol 20.7% (103) 19.9% (68) 22.4% (35) 0.227
Olanzapine 21.1% (105) 24.0% (82) 14.7% (23) –
Quetiapine 20.9% (104) 20.5% (70) 21.8% (34) –
Amisulpride 20.9% (104) 20.2% (69) 22.4% (35) –
Ziprasidone 16.5% (82) 15.5% (53) 18.6% (29) –
DSM-III-R diagnosis – – – 0.603
Disorganized, catatonic,
undifferentiated
8.4% (42) 7.3% (25) 10.9% (17) –
Paranoid 44.8% (223) 45.3% (155) 43.6% (68) –
Schizophreniform 39.8% (198) 40.1% (137) 39.1% (61) –
Schizoaffective 7.0% (35) 7.3% (25) 6.4% (10) –
Psychosocial intervention 14.1% (70) 11.4% (39) 19.9% (31) 0.018
Met needs patient, sum 2.59 ± 2.57 (470) 2.78 ± 2.73 (333) 2.15 ± 2.06 (137) 0.007/0.034
Unmet needs patient, sum 2.04 ± 2.07 (470) 2.19 ± 2.14 (333) 1.66 ± 1.82 (137) 0.012/0.013
MANSA 4.04 ± 0.92 (483) 3.98 ± 0.90 (339) 4.19 ± 0.96 (144) 0.023/0.022
GAF 40.03 ± 13.51 (490) 40.72 ± 13.50 (341) 38.46 ± 13.44 (149) 0.087/0.107
PANSS total score 88.53 ± 20.63 (487) 89.06 ± 20.69 (340) 87.29 ± 20.49 (147) 0.386/0.371
PANSS positive symptoms 23.13 ± 6.19 (489) 23.36 ± 6.17 (340) 22.59 ± 6.23 (149) 0.205/0.138
PANSS negative symptoms 21.23 ± 7.62 (489) 21.14 ± 7.73 (341) 21.42 ± 7.41 (148) 0.714/0.793
CDSS, sum score 5.07 ± 4.87 (488) 5.27 ± 4.88 (341) 4.62 ± 4.84 (147) 0.176/0.140
Prognosis by investigators 3.19 ± 1.19 (495) 3.10 ± 1.18 (342) 3.39 ± 1.19 (153) 0.014/0.014
Compliance (at 1 months) 5.57 ± 1.20 (453) 5.66 ± 1.16 (337) 5.30 ± 1.29 (116) 0.006/0.006
a Significance of differences between baseline completers and dropouts were calculated for continuous/count/ordinal variables with t tests (first
P-value), to control for non-normal distributions with the Mann–Whitney test (second P-value) and with the Chi-square tests for nominal
variables
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Needs and quality of life
Our results suggest that the interrelation between quality of
life and unmet needs is due to cross-sectional rather than
longitudinal association in first-episode patients. The weak
evidence for a longitudinal association challenges the
assumption of a causal interrelation of unmet needs and
quality of life. Using conventional regression, the associ-
ation between earlier unmet needs and subsequent quality
of life found by previous studies was confirmed only if
baseline quality of life was omitted. With the SEM mod-
eling technique, the longitudinal impact of earlier unmet
needs on subsequent quality of life was not confirmed
unless meeting needs were differentiated from needs that
changed to no needs during the study. One would expect
that any non-random, strong effect would have shown up
unequivocally in both longitudinal methodological
approaches used. There are not many longitudinal studies
with which to compare our results. Slade et al. [31] found a
relation of earlier unmet needs with later quality of life.
Fig. 1 Difference between T1
scores and T9 scores expressed
in percent of T1 values (vertical
axis = difference scores).
Sample of completers
(N = 326)
Table 2 Regression model of MANSA sum score at follow-up
(dependent variable) and the following predictors: baseline clinical
variables (Model 1), baseline MANSA sum score, and baseline clinical
variables (Model 2), baseline MANSA sum score, baseline clinical
variables, and sociodemographic variables (Model 3) (N = 326)
B Std B std T P
Model 1a 4.737 .317 14.949 .000
Unmet needs -.057 .023 -.149 -2.488 .013
CDSS score .016 .010 .094 1.574 .117
GAF score .006 .004 .097 1.576 .116
PANSS positive subscale -.003 .008 -.022 -.369 .712
PANSS negative subscale -.001 .006 -.013 -.216 .829
Model 2b 3.659 .374 9.772 .000
Unmet needs -.034 .023 -.089 -1.507 .133
CDSS score .026 .010 .158 2.672 .008
GAF score .004 .004 .073 1.219 .224
PANSS positive subscale -.003 .008 -.025 -.425 .671
PANSS negative subscale -.001 .006 -.007 -.117 .907
MANSA total score .259 .052 .286 4.988 .000
Model 3c 4.399 .493 8.932 .000
Unmet needs -.032 .022 -.082 -1.408 .160
CDSS total score .026 .010 .158 2.671 .008
GAF score .003 .004 .055 .933 .351
PANSS positive subscale -.004 .008 -.027 -.476 .634
PANSS negative subscale .000 .006 -.001 -.025 .980
MANSA total score .236 .052 .261 4.572 .000
Patient age at
randomization
-.020 .008 -.135 -2.581 .010
Gender -.291 .087 -.176 -3.360 .001
Education (in years) .013 .016 .045 .808 .420
Current occupation .081 .094 .050 .869 .385
Psychosocial intervention -.229 .133 -.090 -1.723 .086
Prognosis by investigators -.036 .038 -.052 -.938 .349
Italicised values indicate significant predictors (P \ 0.05)
a R = .193; R-sq = .037; R-sq-k = .022
b R = .327; R-sq = .107; R-sq-k = .090
c R = .420; R-sq = .176; R-sq-k = .145
Fig. 2 SEM model replicating regression model 2 (Table 2)
(N = 330). Only cross-lagged significant paths are depicted, even
though cross-sectional and autoregressive paths were estimated.
Dashed line means nearly significant. Chi-square value = 5.671,
df = 8, P = 0.6840; CFI = 1.000, TLI = 1.037; RMSEA = 0.000,
SRMR = 0.030; Sample of completers with values on all variables
(N = 330)
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Another study [30] using random coefficient models found
an effect of change in unmet needs as well as mean level of
unmet need on quality of life. Earlier longitudinal studies
testing the impact of psychopathology and functioning but
not needs on quality of life proposed weak or no predictors
of subjective quality of life using graphical chain modeling
[27] or regression analysis [28]. Overall, most available
studies confirm a longitudinal effect of unmet needs on
quality of life. Met needs had an even more inconsistent
and weaker association with quality of life in our study. No
study found that more met needs were interrelated with
higher quality of life. Met needs appear to have the
implication of something missing, despite them being met.
In other words, met needs are better than unmet needs, but
cannot be equated with health or well-being. This is in line
with our finding that quality of life was more positively
influenced by unmet needs that diminished than by unmet
needs that were met. Therefore, the reduction in unmet
needs does not enhance quality of life in any case. Meeting
a need means that patients are still in need of help in this
area of life. This result is intuitively compelling. But it
sheds another light on what is measured when assessing
needs, namely, a conglomerate of different aspects of ill-
ness, treatment, and recovery. Granted that treatment
implies the meeting of patient’s needs, treatment only has a
relatively marginal influence on the improving of quality of
life in our sample. But what has caused the change to no
needs that had a stronger impact on quality of life? The
EUFEST trial describes a homogenous sample moving
through very different stages of schizophrenia. At baseline,
patients were in the acute phase and nearly all in hospital
care. At the 12-month follow-up, most were outpatients
and in remission or stabilization phase of their illness.
Additionally, patients suffering from first-episode schizo-
phrenia have a more favorable treatment response than
more chronically ill patients [13]. This might help to
explain why there were so many needs for care that
changed to no needs.
One important question is how unmet needs could be
changed to no needs by treatment? Is there a direct way
from unmet needs to no needs? Is the change to no needs
also a result of treatment, or has this to be understood as a
spontaneous remission? Those questions are difficult to
answer, but we recommend that results based on treatment
needs should be interpreted only in combination with other
measures that validate different aspects of progress.
There are several explanations for the unstable longi-
tudinal interrelation of unmet needs and quality of life
found in this study. A previous study compared first
admitted and long-term hospitalized patients. It detected
stronger associations between needs and quality of life in
the long-term hospitalized sample [26]. As our patients
were all in early stages of schizophrenia, this could explain
the missing associations. In early stages of schizophrenia,
there is considerable change; improving patients may be
more easily influenced in both positive and negative
directions. Other non-treatment factors may outweigh
treatment factors at the beginning of an illness. Longer
established schizophrenia is associated with an increasing
reliance of patients on professionals and health services.
The reduced importance of treatment systems in our early
sample may explain some of the relatively low impact of
Fig. 3 SEM model with same
covariates as the model in
Fig. 2, but including age and
gender, and differentiating
between unmet needs that
change to no needs and unmet
needs that change to met needs
(N = 330). Chi-square
value = 15.037, df = 18,
P = 0.6595; CFI = 1.000,
TLI = 1.010;
RMSEA = 0.000,
SRMR = 0.026; Sample of
completers with values on all
variables (N = 330)
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treatment needs on quality of life in our sample. The
instability of the regression models may also be due to the
different situation (e.g., hospital and outpatient care) of
patients at baseline and at follow-up.
The vast number of possible influences on the relationship
between needs and quality of life in mind helps explain the
inconsistent results in different studies. Further influences
are whether routine outcome data or research data are used,
which diagnostic groups are included and in which stage of
illness and setting (in hospital vs. outpatients) and lastly
treatment received. In addition, there are several quality of
life instruments in use, and needs can be rated by therapists,
research assistants, or the patients themselves.
Other predictors of quality of life
Longitudinal studies of the interrelation of unmet needs
with other outcome measures than quality of life are sparse
and provided inconsistent results. An advantage of the
model used is that it explains the change in quality of life.
By including baseline quality of life, the path from baseline
to follow-up levels of quality of life represents the values
remaining stable. The other paths to quality of life explain
change. In this population of patients, new to their illness,
depression was longitudinally more clearly interrelated
with quality of life than positive and negative symptoms
and unmet needs. Patients with more depression at baseline
had more changes to no needs, and therefore, a better
quality of life at follow-up. The diminishing of unmet
needs was, in addition to higher depression scores, related
to more positive symptoms at baseline. Meeting needs were
predicted by lower depression scores, but not by positive
symptoms. There must be patients with marked symptom
load at baseline who experience alleviation in terms of
diminishing need for care for symptoms. This in turn
influences their subjective quality of life. Interestingly,
there was no direct effect of positive symptoms, but
patients with more depression at baseline tended to have a
better quality of life at follow-up. Functioning was not
associated with quality of life. This is in line with the
finding that social functioning and quality of life are
independent in schizophrenic patients living in the com-
munity [6]. Female gender and younger age consistently
influenced change and quality of life positively. For further
research, it would be interesting to know more about those
complex interrelations.
Future research
In sum, there is a need for research clearing the following
points: The differential impact of needs that disappear and
need that is met on quality of life should be replicated
using more measurements and with different patient
groups. Treatment research is needed to study the processes
that lead to change in needs and to find out what causes
needs to disappear. Experimental studies are necessary to
determine the direction of causality.
Limitations
Naturalistic studies as ours are limited in their capacity to
determine causal effects. If the conditions (independent
variables) are not manipulated experimentally, causal
hypotheses cannot be tested with certainty. No definite
discrimination between correlation and causality is possi-
ble. Results of this study should be interpreted as a first step
in proving that the change from unmet to met needs leads
to an improvement of quality of life.
An impediment on the validity of results was drop out.
This is a problem of most longitudinal studies. Moreover,
there was a difference between patients who completed the
study and patients who dropped out for a variety of reasons.
Adherent patients were those with more needs, higher
quality of life, and better compliance as well as prognosis
at baseline. Strictly speaking, our results are valid only for
first-episode patients with higher baseline quality of life.
We refrained from using imputation of missing data,
because this does not reduce the risk of biased results when
only two measurements are available. More assessments
would allow for better imputation solutions or for calcu-
lating random coefficient models/multilevel models that
use all available information.
Finally, the sample of the EUFEST study might not
represent the average first-episode patient, as patients who
signed informed consent might differ from patients who
did not, all patients were in inpatient treatment, and centers
were not selected randomly.
Conclusions
This study questions the generally accepted assumption
that meeting needs enhance quality of life. During the
transition from acute to more stable phases of illness,
unmet needs are associated with outcome quality of life
only when they have diminished until the outcome
assessment. For further research, it is important to differ-
entiate meeting unmet needs and unmet needs that change
to no needs.
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